Goldman Sachs
AGIO icon

Goldman Sachs’s Agios Pharmaceuticals AGIO Stock Holding History

Goldman Sachs’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,500
Closed -$1.2M – 5955
2022
Q3 		$1.2M Buy
+42,500
New +$1.14M ﹤0.01% 4382
2021
Q4 		– Sell
-27,000
Closed -$1.25M – 6440
2021
Q3 		$1.25M Sell
27,000
-25,300
-48% -$1.22M ﹤0.01% 4581
2021
Q2 		$2.88M Buy
52,300
+20,800
+66% +$1.16M ﹤0.01% 3863
2021
Q1 		$1.63M Sell
31,500
-24,700
-44% -$1.22M ﹤0.01% 4181
2020
Q4 		$2.44M Buy
+56,200
New +$2.22M ﹤0.01% 3578
2020
Q1 		– Sell
-6,600
Closed -$315K – 5187
2019
Q4 		$315K Buy
+6,600
New +$249K ﹤0.01% 4720
2018
Q3 		– Sell
-30,000
Closed -$2.53M – 5547
2018
Q2 		$2.53M Buy
+30,000
New +$2.62M ﹤0.01% 3476
2018
Q1 		– Sell
-41,000
Closed -$2.34M – 5871
2017
Q4 		$2.34M Hold
41,000
– – ﹤0.01% 3648
2017
Q3 		$2.74M Buy
+41,000
New +$2.46M ﹤0.01% 3704
2015
Q3 		– Sell
-48,700
Closed -$5.41M – 7253
2015
Q2 		$5.41M Buy
+48,700
New +$5.25M ﹤0.01% 2889
2015
Q1 		– Sell
-26,500
Closed -$2.97M – 7046
2014
Q4 		$2.97M Buy
+26,500
New +$2.37M ﹤0.01% 3460

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Goldman Sachs's AGIO Position: Q1 2026 in Review

Goldman Sachs reduced its Agios Pharmaceuticals (AGIO) stake by 22% in Q1 2026, selling an estimated $6.47M and leaving 805,776 shares worth $27.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2145.

Goldman Sachs first reported a position in AGIO in Q4 2013 and has held it in 49 quarters since. The position peaked at $110M in Q1 2019. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Goldman Sachs held 805,776 shares of Agios Pharmaceuticals worth $27.3M as of Q1 2026.
  • Goldman Sachs sold 228,198 Agios Pharmaceuticals shares in Q1 2026, an estimated $6.47M.
  • Agios Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2145 holding.
  • Goldman Sachs first reported a position in Agios Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
  • Goldman Sachs's Agios Pharmaceuticals position peaked at $110M in Q1 2019.
  • 233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.